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GlaOBJECTIVES This study aims to investigate the prognostic significance of late gadolinium enhancement (LGE) in
patients without coronary artery disease and with normal range left ventricular (LV) volumes and ejection fraction.
BACKGROUND Nonischemic patterns of LGE with normal LV volumes and ejection fraction are increasingly detected on
cardiovascular magnetic resonance, but their prognostic significance, and consequently management, is uncertain.
METHODS Patients with midwall/subepicardial LGE and normal LV volumes, wall thickness, and ejection fraction on
cardiovascular magnetic resonance were enrolled and compared to a control group without LGE. The primary outcome
was actual or aborted sudden cardiac death (SCD).
RESULTS Of 748 patients enrolled, 401 had LGE and 347 did not. The median age was 50 years (interquartile range: 38
years-61 years), LV ejection fraction 66% (interquartile range: 62%-70%), and 287 (38%) were women. Scan indications
included chest pain (40%), palpitation (33%) and breathlessness (13%). No patient experienced SCD and only 1 LGEþ
patient (0.13%) had an aborted SCD in the 11th follow-up year. Over a median of 4.3 years, 30 patients (4.0%) died. All-
cause mortality was similar for LGEþ/- patients (3.7% vs 4.3%; P ¼ 0.71) and was associated with age (hazard ratio: 2.04
per 10 years; 95% confidence interval: 1.46-2.79; P < 0.001). Twenty-one LGEþ and 4 LGE- patients had an unplanned
cardiovascular hospital admission (hazard ratio: 7.22; 95% confidence interval: 4.26-21.17; P < 0.0001).
CONCLUSIONS There was a low SCD risk during long-term follow-up in patients with LGE but otherwise normal LV
volumes and ejection fraction. Mortality was driven by age and not LGE presence, location, or extent, although the latter
was associated with greater cardiovascular hospitalization for suspected myocarditis and symptomatic ventricular
tachycardia. (J Am Coll Cardiol Img 2021;-:-–-) © 2021 The Authors. Published by Elsevier on behalf of the American
College of Cardiology Foundation. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).N 1936-878X https://doi.org/10.1016/j.jcmg.2021.05.016
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LV = left ventricular
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MRI = cardiovascular magnetic
resonance
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T here has been rapid growth in theadoption of cardiovascular magneticresonance (MRI) imaging for diag-
nostic evaluation, surveillance, and assess-
ment of treatment response across the
spectrum of cardiovascular (CV) disease.
Appropriate-use criteria highlight the evolu-
tion in complexity and capability of MRI
to support clinical decision-making (1,2).
Replacement fibrosis (scar) identified by
late gadolinium enhancement (LGE) indi-
cates an adverse prognosis in many condi-
tions, which are all characterized by
abnormal left ventricular (LV) volumesand/or LV ejection fraction (LVEF) (3-6). However,
myocardial fibrosis remains a powerful predictor of
sudden cardiac death (SCD) even when the severity
of LV dysfunction is only modest (7).
Increasing numbers of individuals are identified
with normal LV volumes, wall thickness, and LVEF
and previously unrecognized myocardial fibrosis. In
one of many series, subendocardial fibrosis suggest-
ing myocardial infarction was present in 17% of peo-
ple older than 67 years of age with incremental
prognostic value beyond standard clinical predictors
including LVEF (8-11). However, there is a paucity of
data on the prognostic significance of nonischemic
fibrosis in the midwall and/or subepicardium of peo-
ple with normal LV volumes, wall thickness, and
LVEF. Fibrosis represents the final common pathway
of injury from a diverse range of diseases and insults
(12). Whether nonischemic fibrosis is a risk factor for
SCD in the absence of other structural markers of
disease such as LV dysfunction/dilation is unknown.
Moreover, the etiology of midwall/subepicardial
fibrosis is often unclear and ascribed to remote
events, such as previous myocarditis. Uncertainty
surrounding the clinical significance and manage-
ment of such cases leads to conflicting advice, such as
refraining from high-intensity exercise, for which
there is no evidence of benefit, multiple in-
vestigations at considerable expense, and some risk
that may also heighten anxiety for the patient, their
family, and their physicians (13).
To the best of our knowledge, no study to date has
specifically investigated the outcome of people with
h
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thor Center.
received June 17, 2020; revised manuscript received April 20, 20normal LV volumes and ejection fraction with non-
ischemic patterns of LGE and no other manifestation
of cardiac disease.
METHODS
PATIENTS. Patients referred for MRI between 2003
and 2016 with midwall and/or subepicardial LV
myocardial fibrosis were identified. Exclusion criteria
were applied in a stepwise approach (Figure 1). Filters
were used to exclude all patients with LV wall thick-
ness >12 mm, LV end-diastolic volume index
(LVEDVi) >103 mL/m2, LV end-systolic volume index
(LVESVi) >41 mL/m2 and LV mass index >93 g/m2
based on the upper 95% confidence interval (CI) for
men aged 20 years-29 years (14). All men aged
>29 years and all women regardless of age would
have indexed volumes below these upper thresholds.
Then, patients with a potential reason for myocardial
fibrosis, such as active myocarditis, sarcoidosis, pre-
vious chemotherapy, recovered dilated cardiomyop-
athy, or aortic stenosis were excluded. Similarly, we
excluded patients with resuscitated cardiac arrest,
where the need for implantable cardioverter-
defibrillator (ICD) implantation for secondary pre-
vention was already established. Patients with
controlled hypertension receiving treatment with 1 or
2 antihypertensive agents at baseline were included,
but not those with resistant hypertension (15). Pa-
tients with >50% stenosis in a major coronary artery,
infarct pattern of LGE, left bundle branch block, cor-
onary bypass grafting, or percutaneous intervention
were also excluded. Finally, MRI data for remaining
individuals were manually curated to exclude
indexed LV values outside the appropriate age- and
sex-adjusted normal ranges (14). In total, 456 patients
met the stringent criteria to define a structurally
normal heart (Figure 1).
In addition, a cohort of patients referred for MRI
between 2003 and 2016 without myocardial fibrosis
on LGE imaging (LGE-) provided a control cohort.
These individuals were matched by scan indications.
Inclusion and exclusion criteria were otherwise
identical.
Patients provided written informed consent for the
collection of clinical baseline and follow-up data ases and animal welfare regulations of the authors’
t consent where appropriate. For more information,
21, accepted May 24, 2021.
FIGURE 1 Patient Consort Flow Diagram
15,698 patients screened from the RBH
routine clinical service from 2003-2016
1,625 patients assessed for alternative
diagnoses
1,203 patients assessed for abnormal
indexed CMR criteria
• 40 patients withheld consent to access information
• 15 patients moved abroad
747 patients excluded:
• 306 due to abnormal ejection fraction
• 258 due to abnormal indexed LVEDV
• 158 due to increased wall thickness
• 10 due to regional wall motion abnormality
• 9 due to unrecognised subendocardial infarction
• 6 due to increased LV mass
422 patients excluded:
• 129 co-existent subendocardial infarction
• 89 previous cardiac intervention
• 77 moderate or severe valvular heart disease
• 46 recovered dilated cardiomyopathy
• 24 hypertrophic cardiomyopathy
• 16 resuscitated cardiac arrest
• 13 cardiac sarcoidosis
• 9 acute myocarditis
• 7 left ventricular non-compaction
• 5 Takotsubo cardiomyopathy
• 3 left-bundle branch block
• 2 amyloidosis
• 2 scleroderma
Keyword search to include patients with:
• Fibrosis AND [Mid-wall AND/OR septal AND/OR
   subepicardial]
Filtered to exclude:
• LV wall thickness >12 mm
• LVEDVi >103 ml/m2
• LVESVi >41 ml/m2
• LV mass index >93 g/m2
456 patients met study inclusion criteria
401 patients entered into outcome analysis
Consort diagram shows the identification, inclusion and exclusion of the study population. CMR¼ cardiac magnetic resonance; RBH ¼ Royal
BerkshireHospital; LV¼ left ventricular; LVEDVi¼ left ventricular end-diastolic volume index; LVESVi¼ left ventricular end-systolic volume index.
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approved and directed by the National Research
Ethics Service and received Institutional Board
Approval by the Royal Brompton Hospital. The data
supporting the findings of this study are available
from the corresponding author upon request.
MRI IMAGE ACQUISITION AND ANALYSIS. MRI was
performed on 1.5-T scanners (Sonata/Avanto) using a
standardized protocol as previously described(Supplemental Methods). The presence, extent, and
location (septal vs nonseptal) of midwall/sub-
epicardial fibrosis was assessed by 2 independent
expert readerswhowere blinded to clinical data,with a
third senior expert providing adjudication if necessary
(Figure 2). LGE mass (g) was quantified using the full-
width at half-maximum technique and indexed as a
percentage of LV mass (Supplemental Figure 1).
FIGURE 2 Typical MRI Late Gadolinium Enhancement Images
Mid-ventricular short-axis views for 4 patients with normal indexed left ventricular volumes, wall thickness and ejection fraction demon-
strating; (A) sub-epicardial enhancement in the inferolateral wall, (B) sub-epicardial enhancement in the anterolateral wall, (C) linear mid-
wall enhancement in the septum, (D) mid-wall enhancement of the septum and sub-epicardial enhancement of the anterior, lateral and
inferior walls. MRI ¼ magnetic resonance.
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FOLLOW-UP AND OUTCOMES. Patient follow-up was
performed retrospectively by postal questionnaires,
telephone interviews, and retrieval of information
from primary care and hospital records. The presence
of a family history of SCD was sought for all cases.
Deaths were identified through the UK Health and
Social Care Information Service. The prespecified
primary outcome was a composite of actual or abor-
ted SCD, as defined previously (16). The principal
secondary outcome was all-cause mortality and a
composite of CV mortality (SCD, heart failure, stroke,
or thromboembolism) and unplanned CV hospitali-
zation. Follow-up duration was calculated from the
date of baseline MRI and censored at the first event or
last patient contact. All clinical data were recorded in
an electronic database and adjudicated by an inde-
pendent committee of cardiologists blinded to MRI
data. Cause of death was established from death
certification and postmortems.STATISTICAL ANALYSIS. Baseline characteristics
(LGEþ vs LGE-) were compared using the Mann-
Whitney U test or Fisher exact test. Patients with
septal and nonseptal LGE were included in the septal
group, given that septal and multiple patterns of LGE
were previously recognized as the main drivers of
arrhythmic risk (16). Medication was recorded at the
time of baseline scan. Cumulative incidence curves
were generated for outcomes with event times
measured from the baseline MRI date. Associations
between the location/extent of fibrosis and outcomes
were analyzed using uni- and multivariable Cox pro-
portional hazards modelling adjusted for known
important predictors of outcome including age, sex,
New York Heart Association (NYHA) functional class,
and atrial fibrillation. The proportional hazards
assumption was tested for the univariable and
multivariable Cox models using plots of scaled
Schoenfeld residuals and by testing the inclusion of
TABLE 1 Baseline Patient Demographics for the 2 Study Groups Defined by the Presence or Absence of Nonischaemic Late Gadolinium
Enhancement (LGEþ/-)
All Patients (N ¼ 748)
LGE
P ValueNo (n ¼ 347) Yes (n ¼ 401)
Age, y 50 (38-61) 49 (37-59) 51 (39-62) 0.11
Female 287 (38.4) 175 (50.4) 112 (27.9) <0.0001
Body surface area, m2 1.9 (1.7-2.1) 1.9 (1.7-2.0) 1.9 (1.8-2.1) <0.0001
Atrial fibrillation 42 (5.6) 17 (4.9) 25 (6.2) 0.43
Hypertension 173 (23.1) 53 (15.3) 120 (29.9) <0.0001
Diabetes mellitus 56 (7.5) 22 (6.3) 34 (8.5) 0.27
Hypercholesterolaemia 127 (17.0) 59 (17.0) 68 (17.0) 0.99
Current smoker 58 (7.8) 21 (6.1) 37 (9.2) 0.11
Cerebrovascular accident 15 (2.0) 2 (0.6) 13 (3.2) 0.010
Excess alcohol 98 (13.1) 50 (14.4) 48 (12.0) 0.32
Family history of sudden cardiac death 35 (4.7) 14 (4.0) 21 (5.2) 0.44
Medication
ACE inhibitor 113 (15.1) 37 (10.7) 76 (19.0) 0.002
Beta blocker 186 (24.9) 66 (19.0) 120 (29.9) <0.001
Angiotensin receptor blocker 55 (7.4) 13 (3.7) 42 (10.5) <0.001
Anti-arrhythmia medication 36 (4.8) 15 (4.3) 21 (5.2) 0.56
New York Heart Association functional class
I 624 (83.4) 320 (92.2) 304 (75.8) <0.0001
II 120 (16.0) 27 (7.8) 93 (23.2)
III 4 (0.5) 0 (0.0) 4 (1.0)
Scan indication
Chest pain 300 (40.1) 139 (40.1) 161 (40.1) 0.64
Palpitation or syncope 248 (33.2) 112 (32.3) 136 (33.9)
Breathlessness 98 (13.1) 43 (12.4) 55 (13.7)
Asymptomatic family screen 80 (10.7) 41 (11.8) 39 (9.7)
Other 12 (1.6) 5 (1.4) 7 (1.7)
Aortic assessment 10 (1.3) 7 (2.0) 3 (0.7)
MRI parameters
LVEDVi, mL/m2 77 (66-85) 74 (64-83) 79 (69-87) <0.0001
LVESVi, mL/m2 25 (21-31) 24 (19-29) 26 (22-32) <0.0001
LVEF, % 66 (62-70) 67 (63-72) 66 (62-69) 0.002
LV mass index, g/m2 63 (54-71) 59 (51-70) 66 (58-73) <0.0001
RVEDVi, mL/m2 78 (68-89) 75 (64-87) 81 (71-91) <0.001
RVESVi, mL/m2 30 (24-37) 29 (23-37) 31 (25-37) 0.03
RVEF, % 61 (56-66) 61 (56-66) 61 (56-65) 0.85
LGE, g 2.80 (1.50-5.25) - 2.80 (1.50-5.25)
LGE, % 2.24 (1.21-4.14) - 2.24 (1.21-4.14)
LGE >2.25% 202 (27.0) - 202 (50.4)
Values are median (interquartile range) or n (%).
ACE ¼ angiotensin-converting enzyme; LGE ¼ late gadolinium enhancement; LV ¼ left ventricular; LVEDVi ¼ left ventricular end-diastolic volume index; LVEF ¼ left
ventricular ejection fraction; LVESVi ¼ left ventricular end-systolic volume index; MRI ¼ magnetic resonance imaging; RVEDVi ¼ right ventricular end-diastolic volume index;
RVESVi ¼ ventricular end-systolic volume index.
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an interaction term between time and each explana-
tory variable. To ensure that any observed effect was
not driven by difference between LGEþ/- cohorts at
baseline, a sensitivity analysis was performed
adjusting for additional potential confounders. Re-
sults are presented as hazard ratios (HRs) with
95% CIs. Statistical analyses were performed using
Stata version 14 (StatCorp). A P value of < 0.05 was
considered significant.RESULTS
From 15,698 patients scanned with contrast in our
institution from 2003 to 2016, 1,625 patients were
identified for further evaluation into the LGEþ group
(Figure 1). Of these, 422 (26%) were excluded due to
coexistent pathology. Of the remaining 1,203 pa-
tients, 747 (62%) were excluded due to abnormalities
of indexed LV measurements. As a result, 456
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347 58263 185 147 106No LGE
Number at risk
202LGE ≤2.25% 11152 103 53 32
199LGE >2.25% 8143 106 63 21
P < 0.0001
2B
No LGE LGE ≤2.25% LGE >2.25%
No LGE LGE ≤2.25% LGE >2.25%
No LGE LGE
No LGE LGE
Cumulative incidence of (1) all-cause mortality and (2) CV death, aborted SCD and CV hospitalization stratified by (A) the presence or absence of LGE and (B) LGE extent
above or below the median of 2.25% in this cohort with comparison to the LGE- group. CV ¼ cardiovascular; SCD ¼ sudden cardiac death; LGE ¼ late gadolinium
enhancement.
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patients met inclusion and exclusion criteria. Of
these, 40 withheld consent to follow-up and 15 had
emigrated. Therefore, the LGEþ group consisted of
401 patients. A total of 347 LGE- patients were iden-
tified over the same period with matching scan
indications, resulting in an overall cohort of 748
people.BASELINE CHARACTERISTICS. Themedian age of the
overall cohort was 50 y (interquartile range [IQR]: 38
years-61 years) and 287 (38%) were women
(Table 1, Supplemental Figure 2). The main scan in-
dications were chest pain (40%), palpitation/syncope
(33%), or breathlessness (13%) (Supplemental
Figure 3). A family history of SCD was reported for 35
TABLE 2 Univariable Predictors of All-Cause Mortality (Presented as HRs and 95% CIs)
HR (95% CI) P Value
Age (per 10-y increase) 2.04 (1.49-2.79) <0.0001
Female 1.35 (0.66-2.76) 0.42
Body surface area (m2) 0.38 (0.08-1.83) 0.23
Atrial fibrillation 1.46 (0.35-6.12) 0.61
Hypertension 0.79 (0.32-1.93) 0.61
Diabetes mellitus 0.38 (0.05-2.82) 0.35
Hypercholesterolaemia 4.13 (2.01-8.47) <0.001
Current smoker 0.38 (0.05-2.82) 0.35
Cerebrovascular accident 0.00 (0.00-0.00) 1.00
Excess alcohol 1.77 (0.76-4.14) 0.18
Family history of sudden cardiac death 0.62 (0.08-4.55) 0.64
Medication
ACE inhibitor 1.35 (0.55-3.29) 0.52
Beta blocker 0.76 (0.31-1.87) 0.56
ARB 0.40 (0.05-2.90) 0.36
Anti-arrhythmia medication 0.62 (0.08-4.56) 0.64
New York Heart Association functional class
I Ref.
II/III 2.33 (1.07-5.10) 0.03
MRI parameters
LVEDVi (mL/m2) 0.98 (0.95-1.00) 0.08
LVESVi (mL/m2) 0.96 (0.91-1.01) 0.13
LVEF (%) 1.02 (0.95-1.08) 0.63
LV mass index (g/m2) 0.99 (0.96-1.02) 0.48
RVEDVi (mL/m2) 0.98 (0.96-1.00) 0.11
RVESVi (mL/m2) 0.97 (0.93-1.01) 0.09
RVEF (%) 1.04 (0.99-1.09) 0.16





ARB ¼ angiotensin receptor blocker; other abbreviations as in Table 1.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . - , N O . - , 2 0 2 1 Lota et al.
- 2 0 2 1 :- –- The FINALIZE Study
7
patients (5%). Most patients were NYHA functional
class I (83%) or II (15%). Overall, 25% were receiving
beta blockers, mostly for palpitation or chest pain, and
22% were receiving angiotensin-converting enzyme
(ACE) inhibitors or angiotensin receptor blockers
(ARBs), primarily for hypertension. The median
LVEDVi was 77 mL/m2 (IQR: 66-85 mL/m2), LVESVi
25 mL/m2 (IQR: 21-31 mL/m2) and LVEF 66% (IQR: 62%-
70%). LGE patterns were found to be septal in 69 (17%)
patients, nonseptal in 305 (76%), and both septal and
nonseptal in 27 (7%). The median LGE mass in the
LGEþ group as a percentage of overall LV mass was
2.25% (IQR: 1.21%-4.14%).
LGEþ patients were more likely to be men
(P < 0.0001) with a history of controlled hypertension
(P < 0.0001) and receiving treatment with a beta
blocker or ARB (P < 0.001). NYHA functional class was
also more likely to be II/III (P < 0.0001). LGE- patients
were more likely to be women and have lower LVEDVi
(P < 0.0001), and lower LV mass index (P < 0.0001)
within the normal ranges. There were no significant
differences between groups in age, comorbidity, or
scan indication.
In the LGEþ group, those with nonseptal LGE were
more likely to be men (P ¼ 0.029) and to present with
chest pain (P < 0.0001). Patients with septal LGE were
more likely to be women (P ¼ 0.029), to present with
breathlessness or for familial cardiomyopathy
screening (P < 0.0001), to have atrial fibrillation
(P ¼ 0.028), and to be prescribed an ACE inhibitor (P ¼
0.027). There were no significant differences between
groups in age, baseline medical history, or medication.
PRIMARY OUTCOME. Over a median follow-up of
4.3 y (IQR: 2.1 years-6.5 years), only 1 patient (0.13%
of the total cohort; 0.2% of the LGEþ group) met the
primary outcome, presenting with an aborted SCD.
This event occurred during the 11th year of follow-up
in a patient who had a primary prevention ICD, basal-
septal LGE, and no family history of SCD. The inci-
dence rate per 100 patient-years in the LGEþ group
was 0.05 (95% CI: 0.008-0.39) (Figure 3A).
In the LGEþ group, 11 patients had an ICD
implanted for primary prevention without LV dilata-
tion or reduction in LVEF; however, because of
symptomatic episodes of nonsustained ventricular
tachycardia (NSVT; 7 patients), asymptomatic NSVT
with a family history of SCD (1 patient), or identifi-
cation of clinically significant genetic variants with a
family history of SCD (3 patients; Lamin A/C, desmin,
and desmoplakin) (Supplemental Table 1). Seven pa-
tients had an elective radiofrequency ablation pro-
cedure for NSVT. Thus, 18 LGEþ patients had an
intervention for ventricular arrhythmia, of which 5had septal LGE. In the LGE- group, 2 patients had a
primary prevention ICD, and none had an interven-
tion for ventricular arrhythmia.
SECONDARY OUTCOMES. All-cause mortality. There
were 30 deaths during follow-up (4.0% of the total
cohort), of which 2 were cardiovascular. The rate was
similar for patients with (3.7%) and without (4.3%)
LGE (P ¼ 0.71). All-cause mortality was associated
with patient age (HR: 2.04 per 10-year increase;
95% CI: 1.46-2.79; P < 0.001) and hypercholesterole-
mia (HR: 4.13; 95% CI: 2.01-8.47; P < 0.001) (Figure 3B,
Table 2). The etiology for CV death was worsening
heart failure from newly developed ischemic heart
disease (both in men aged >70 years). Non-CV deaths
included cancer (18 patients; 64%), pneumonia (7
patients; 25%), end-stage renal failure (1 patient),
leukemia (1 patient), and motor neuron disease (1
patient). There was no association between LGE
location or extent and all-cause mortality.
TABLE 3 Univariable and Multivariable Analyses for the Composite Secondary Outcome of CV Death, Aborted SCD and Unplanned CV
Hospitalization
Univariable Multivariable
HR (95% CI) P Value HR (95% CI) P Value
Age, y 1.07 (0.84-1.37) 0.58 1.04 (0.81-1.33) 0.77
Female 0.62 (0.27-1.42) 0.26 1.00 (0.42-2.37) 1.00
Body surface area, m2 3.48 (0.77-15.62) 0.10
Atrial fibrillation 3.48 (1.20-10.06) 0.02 3.62 (1.20-10.98) 0.02
Hypertension 1.52 (0.69-3.36) 0.30
Diabetes mellitus 1.30 (0.39-4.31) 0.67
Hypercholesterolaemia 1.01 (0.38-2.66) 0.98
Current smoker 3.77 (1.60-8.88) 0.002
Cerebrovascular accident 8.26 (2.86-23.85) <0.0001
Excess alcohol 1.27 (0.48-3.34) 0.63
Family history of sudden cardiac death 0.66 (0.09-4.84) 0.68
Medication
ACE inhibitor 1.78 (0.76-4.19) 0.19
Beta blocker 3.09 (1.47-6.49) 0.003
ARB 0.87 (0.21-3.66) 0.85
Anti-arrhythmia medication 5.70 (2.31-14.06) <0.001
New York Heart Association functional class
I Ref. Ref.
II/III 2.26 (0.99-5.14) 0.05 1.47 (0.61-3.52) 0.39
MRI parameters
LVEDVi, mL/m2 1.00 (0.97-1.03) 0.87
LVESVi, mL/m2 1.01 (0.96-1.06) 0.59
LVEF, % 0.96 (0.90-1.02) 0.19
LV mass index, g/m2 0.99 (0.96-1.02) 0.36
RVEDVi, mL/m2 1.00 (0.98-1.03) 0.82
RVESVi, mL/m2 1.00 (0.96-1.04) 0.95
RVEF, % 1.01 (0.96-1.06) 0.74




>2.25% 11.27 (3.73-34.07) <0.0001
CV ¼ cardiovascular; SCD ¼ sudden cardiac death; other abbreviations as in Table 1.
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CV death, aborted SCD, and unplanned
hospitalization. During follow-up, there were 2 CV
deaths and 73 CV hospital admissions (9.7% of the
total cohort), of which 25 (34%) were unplanned.
Twenty-one of 401 LGEþ patients (5.2%) experienced
this composite outcome compared with 4 of 347 LGE-
patients (HR: 7.22; 95% CI: 4.26-21.17; P < 0.0001).
Indications for unplanned admissions included a
first-confirmed episode of myocarditis (n ¼ 7), palpi-
tation due to NSVT (n ¼ 5), cerebrovascular accident
(CVA; n ¼ 4), pacemaker implantation (n ¼ 3), atrial
fibrillation (n ¼ 2), myocardial infarction (n ¼ 2), and
pulmonary embolism (n ¼ 2). Of those admitted for
investigation of palpitation with NSVT, all were LGEþ
and underwent radiofrequency ablation and/or ICD
implantation as outlined above. In patients with LGEand an event, 79% had an LGE mass index above the
median of 2.25% (LGEþ HR: 11.27; 95% CI: 3.73-34.07
vs LGE- HR: 3.55; 95% CI: 0.99-12.75; P < 0.0001)
(Figure 3D). Other variables that showed an associa-
tion on univariable analysis (Table 3) included prior
CVA (HR: 8.26; 95% CI: 2.86-23.85; P < 0.0001) and
prescription of beta blockers (HR; 3.09; 95% CI: 1.47-
6.49; P ¼ 0.003) or other antiarrhythmical medication
(HR: 5.70; 95% CI: 2.31-14.06; P < 0.001).
In a multivariable analysis adjusting for age, sex,
atrial fibrillation, and NYHA functional class, LGE
presence remained associated with this secondary
composite outcome (HR: 7.16; 95% CI: 2.30-22.58; P ¼
0.001). There was no strong evidence that the pro-
portional hazards assumption was violated for any
explanatory variable in the models. Additionally, we
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performed a sensitivity analysis (including hyperten-
sion, current smoker, previous CVA, and any medica-
tion use) to confirm that LGE presence remained
associated with this endpoint after adjustment for
imbalances of between groups (HR: 6.51; 95% CI: 2.06-
20.58; P ¼ 0.001) (Supplemental Table 2).
GENETIC SEQUENCING. Thirteen of 39 LGEþ pa-
tients (33%) with a family history of cardiomyopathy
as the scan indication (although phenotypically un-
affected) were subsequently found to have rare vari-
ants in genes associated with cardiomyopathy
(Supplemental Table 1). Of these patients, 3 had ICDs
implanted for primary prevention; however, none
met the primary outcome, and only 2 met the com-
posite secondary outcome. Sensitivity analysis
confirmed that the primary study findings were not
altered significantly by the inclusion or exclusion of
this group.
DISCUSSION
Management of patients with midwall/subepicardial
fibrosis in the setting of normal LV volumes and ejec-
tion fraction is a clinical conundrum due to the lack of
data on how to manage and advise such patients. This
is the first study to investigate the prognostic signifi-
cance of nonischemic patterns of LGE in patients with
normal LV volumes and ejection fraction. Overall,
there was a low burden of major arrhythmic events
during a median follow-up of 4.3 years. All-cause
mortality was driven primarily by age-related disease
and was not associated with presence or absence of
LGE (Central Illustration). However, there was an in-
crease in the burden of unplanned CV hospitalization
among patients with LGE, particularly among those
with a greater volume of LGE, independent of age.
SCD remains a major public health issue with
devastating impact. Traditional approaches to risk
stratification are imprecise and reliant on LVEF.
However, the vast majority of SCDs occur among pa-
tients either not diagnosed with heart disease (45% of
patients) or with a history of heart disease but LVEF >
40% (40% of patients) (17). As emphasized in the 2017
American Heart Association guidelines for manage-
ment of patients with ventricular arrhythmias, there
is unmet need to improve the identification of in-
dividuals without ventricular dysfunction who are at
risk for SCD. In our cohort, there was a low overall
burden of major arrhythmic events. The only aborted
SCD event occurred in a patient with septal LGE. The
underlying arrhythmia that triggered an appropriate
shock was monomorphic ventricular tachycardia
initiated by a premature ventricular ectopic coupletoccurring during sinus tachycardia. This suggests that
patients with incidental and otherwise unexplained,
nonischemic patterns of LGE do not require ICD im-
plantation if LV volumes, wall thickness, and ejection
fraction are all within normal limits. Furthermore,
this observation supports the notion that the genesis
of ventricular arrhythmia is dependent on the pres-
ence of multiple factors, of which structural substrate
is just one component. Our data suggest that
replacement myocardial fibrosis in a nonischemic
pattern in the absence of other risk factors, such as LV
dilatation, reduced LVEF, or a family history of car-
diomyopathy, is not a marker of high risk even over
an extended period of follow-up.
Our results should be considered in the context
of other studies investigating the significance of
LGE in patients with no known CV disease. In 939
patients (median age: 76 years) from the Age, Gene/
Environment Susceptibility (AGES)–Reykjavik study,
incidental infarct-pattern LGE was detected in 17%
and this was independently associated with all-
cause mortality (8). Similarly, in 310 patients with
LVEF > 50%, infarct-pattern LGE predicted cardiac
transplantation and all-cause mortality (10). In a
study of 44 patients with myocardial infarction, the
presence of even small amounts of LGE (<2% mean
LV mass) was associated with a 7-fold increase in
the HR for major adverse cardiac events, and
remained an independent predictor when adjusted
for LVEF (11). In our study, mortality was associated
with increasing age and hypercholesterolemia rather
than presence/absence of LGE; the low CV mortality
in our cohort may reflect the stringent exclusion of
patients with coronary artery disease. We confirmed
the excellent negative predictive value of an
entirely normal MRI scan reported in a previous
study of 225 patients with clinically suspected
myocarditis, in which no patient with a normal MRI
had a major cardiovascular event over >4 years of
follow-up (18).
In a subgroup analysis of the AGES–Reykjavik
cohort, 54 patients (6%) were identified with
“major” nonischemic patterns of LGE attributed to
myocarditis, infiltrative cardiomyopathy, or patho-
logical hypertrophy (19). LGE was associated with a
primary composite endpoint of all-cause mortality
and heart failure hospitalization (HR: 3.2), and it was
associated with a poorer outcome than infarct-
pattern LGE, which was present in 211 (23%)
patients (HR: 2.3). This study emphasized the prog-
nostic significance of etiologically heterogeneous,
nonischemic scar in a relatively small number of in-
dividuals with normal LVEF (median: 62%) but later
CENTRAL ILLUSTRATION Prognostic Relevance of Nonischaemic Late Gadolinium Enhancement
in the Absence of Other Features of Structural Heart Disease
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Take-away message:
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suggest a cardiomyopathy have a favourable long-term outcome
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Non-ischaemic late gadolinium enhancement by cardiovascular magnetic resonance in the absence of other risk factors, such as LV dilatation,
increased wall thickness, reduced LVEF or a family history of cardiomyopathy, is associated with a favorable long-term outcome.
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10in life with greater levels of comorbidity compared to
our cohort.
Understanding of the dose-response relationship
between LGE extent and SCD in any cardiac disease
remains challenging. In our study, patients with
higher volumes of LGE were more likely to have CV
hospitalization, mainly due to concerns about
myocarditis or palpitation/arrhythmia. However,
there were insufficient numbers of events to evaluate
LGE extent as a continuous variable. Nevertheless,
abnormal test results are likely to increase surveil-
lance and it is unclear to what extent the test result
rather than underlying disease drove hospitalization
rates, including ICD implantation and ablation pro-
cedures. The relationship between greater medica-
tion use and the composite secondary outcome may
reflect a higher burden of disease; however, pre-
scribing bias should also be considered. Ambulatoryelectrocardiograph monitoring was not performed
routinely; therefore, the true burden of subclinical
arrhythmia is unknown.
In our cohort, underlying etiology of LGE in
patients with otherwise normal LV volumes and
ejection fraction was often uncertain, reflecting real-
world clinical practice. Lateral free-wall LGE is often
ascribed to a previous, potentially silent, episode of
myocarditis (20). The prevalence of myocarditis is
likely to be globally underestimated. Myocarditis ac-
counts for 11.6% of all SCD found in patients who
are <35 y of age, and yet is only detected on 2% of SCD
postmortem studies, suggesting widespread under-
recognition of this potentially arrhythmogenic
substrate (21,22). Explanations for lateral wall predi-
lection include greater susceptibility of watershed
territories to parvovirus B19-mediated endothelial
dysfunction and polyserositis from the adjacent
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11pericardium. In our cohort, most patients had lateral-
wall LGE, and of these, a greater percentage were
men and presented with chest pain, all typical of
myocarditis.
Lateral-wall LGE may be seen with other pathol-
ogies such as lamin cardiomyopathy, early pre-
sentations of left-dominant forms of arrhythmogenic
cardiomyopathy, Duchenne’s muscular dystrophy
cardiomyopathy, or Anderson-Fabry disease before
LV hypertrophy. Although it is possible that many of
our patients had a remote episode of myocarditis,
other genetic forms of cardiomyopathy are also a
consideration (12). In our cohort, the main revised
diagnosis downstream was of gene carrier status. No
other patients developed a new diagnosis on follow-
up that may have accounted for their initial
presentation.
Whereas genetic cardiomyopathies are generally
associated with adverse outcomes, the event rate in
the preclinical phase of disease with normal LV vol-
umes and ejection fraction is low, as observed in our
cohort. Lamin cardiomyopathy is strongly associated
with malignant arrhythmia and a prognostic model of
4 risk factors was recently proposed consisting of
LVEF < 45%, NSVT, male sex, and Lamin A/C muta-
tion and presence of a pathogenic Lamin A/C variant.
However, no malignant ventricular arrhythmia
occurred in patients with <2 risk factors (23). There is
also emerging evidence of an overlap between
myocarditis and arrhythmogenic ventricular cardio-
myopathy. However, lamin cardiomyopathy and
arrhythmogenic ventricular cardiomyopathy are both
progressive diseases, associated with poor outcome
in the setting of even mild LV dysfunction; therefore,
they require close follow-up.
STUDY LIMITATIONS. The patient cohort was
enrolled from a single center; therefore, it may be
susceptible to referral bias. However, our referral
base for MRI is broad and includes a range of sec-
ondary and tertiary centers. After several levels of
filtering, the final LGEþ study cohort comprised 401
patients from a pool of 15,698 patients. This reflects
the stringency of our algorithm. Ethnicity is known to
influence LV measurements, particularly wall thick-
ness, and the findings of this study are mostly appli-
cable to Caucasians.
The normal range criteria used in this study were
described in a study of 120 healthy people aged 20- to
80-years old (14). Other groups have sought to char-
acterize normal ranges in larger cohorts, such as theUK Biobank (24). In this study, after multiple exclu-
sion steps, 802 (16.2%) healthy participants were
identified with upper LVEDVi cutoffs of 110 mL/m2
(men) and 94 mL/m2 (women) irrespective of age. LV
papillary muscles were included in the LV cavity;
therefore, whereas ventricular volumes tended to be
larger as expected, this did not materially affect
interpretation of our data. The full-width at half-
maximum method was used to quantify LGE, which
may underestimate LGE quantity but provides the
highest intra- and interobserver reproducibility
(25,26).
Follow-up MRI data were not available to evaluate
the presence of adverse remodelling in LGEþ pa-
tients. MRI assessment of extracellular volume, a
preclinical biomarker of reactive interstitial fibrosis,
using T1 mapping was not available at the beginning
of the study. Retrospective MRI assessment of
myocardial strain may help to confirm whether dia-
stolic dysfunction was a significant contributor to
NYHA functional class III status identified in 3.5% of
LGEþ patients, although left atrial size and when
available plasma brain natriuretic peptide were
normal, suggesting that noncardiac comorbidities
may have contributed to symptoms. Similarly,
routine genetic sequencing might have provided
additional insight into etiology.
Given the identification of a single aborted SCD
event, it is challenging to confirm whether this rep-
resents a true negative study outcome or a type II
error. Future work is required with larger patient
groups, but this initial study suggests this patient
group is at a very low risk of SCD.
CONCLUSIONS
Our data provide new information on the prognostic
significance of nonischemic patterns of LGE in a large,
well-characterized cohort of patients with normal LV
volumes and ejection fraction. We demonstrate, for
the first time, that there is a reassuringly low risk of
actual or aborted SCD in this population. All-cause
mortality was driven primarily by age-related dis-
ease and was not associated with the presence of LGE.
These findings do not support aggressive medical
management or the routine use of ICD implantation
within this cohort.
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